Martina Makrutzki

TL;DR: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers and preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis.

TL;DR: The primary endpoint was disease-free survival, analysed for all randomised patients with stage III disease, and the most common grade 3-5 adverse events were neutropenia.

TL;DR: In this study, vemurafenib had prolonged efficacy in patients with BRAF V600–mutant ECD and LCH and warrants consideration as a new standard of care for these patients.

TL;DR: The study demonstrates clinically meaningful response rates of melanoma BM to vemurafenib, which was well tolerated and without significant CNS toxicity, as well as similar in type, grade and frequency to other studies of single-agent vemurAFenib.

TL;DR: Vemurafenib demonstrated evidence of durable antitumor activity in some patients with BRAFV600-mutant gliomas, although efficacy seemed to vary qualitatively by histologic subtype.